Our results demonstrate that MLL4, through the NF-κB-MLL4 regulatory axis, exacerbates steatohepatitis in the context of an inflammatory response and represents a potential therapeutic target for NASH. The gene discussed is KMT2D; the disease is metabolic dysfunction-associated steatohepatitis.